Eric Lefkofsky, founder and CEO of Tempus, was able to raise $200 million for his ventures in accelerated cancer research in late 2020, with Google being a first-time contributor to the cause. Now, valued at over $8 billion, the company is considered to be Chicago’s most valuable startup (Patch).
Tempus pharmaceutical uses artificial intelligence in order to gain a better understanding and more accurately diagnose and combat cancer. It is estimated that Tempus has collected oncology information on every one in three Americans with cancer. Although it was launched in 2015, it now owns the largest catalogue of clinical data in the world. As of 2020, the company began branching out into areas of neurology and psychiatry, as Eric Lefkofsky explained. They now offer testing for those diagnosed with a psychiatric condition, which can help the physician better understand and analyze their patient’s condition and determine the best way to assist them.
In January 2021, the beta version of Tempus ONE was released. The Tempus ONE is a small, portable device that can be used to provide physicians with real-time, accurate data from Tempus’ vast library of information. A few months after its release, Tempus revealed the new Lens platform. By utilizing this, Eric Lefkofsky points out, oncologists can visually analyze and add on to data pertaining to genomic profiling. Tempus is expected to continue growing and innovating in order to introduce an era of advanced cancer research and make it a reality.